[1]王雪云,孫 敏,趙巧云,等.聚乙二醇干擾素聯合富馬酸替諾福韋治療慢性乙型肝炎的療效觀察[J].醫學信息,2020,(04):144-146.[doi:10.3969/j.issn.1006-1959.2020.04.046]
 WANG Xue-yun,SUN Min,ZHAO Qiao-yun,et al.Observation on the Efficacy of Pegylated Interferon Combined with Tenofovir Fumarate in the Treatment of Chronic Hepatitis B[J].Medical Information,2020,(04):144-146.[doi:10.3969/j.issn.1006-1959.2020.04.046]
點擊復制

聚乙二醇干擾素聯合富馬酸替諾福韋治療慢性乙型肝炎的療效觀察()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2020年04期
頁碼:
144-146
欄目:
藥物與臨床
出版日期:
2020-02-15

文章信息/Info

Title:
Observation on the Efficacy of Pegylated Interferon Combined with Tenofovir Fumarate in the Treatment of Chronic Hepatitis B
文章編號:
1006-1959(2020)04-0144-03
作者:
王雪云孫 敏趙巧云
(1.青島大學研究生院,山東 青島 266071;2.濟寧市傳染病醫院,山東 濟寧 272031;3.青島大學附屬醫院感染性疾病科,山東 青島 266071)
Author(s):
WANG Xue-yunSUN MinZHAO Qiao-yunet al
(1.Graduate School,Qingdao University,Qingdao 266071,Shandong,China;2.Jining Infectious Disease Hospital,Jining 272031,Shandong,China;3.Department of Infectious Diseases,the Affiliated Hospital of Qingdao University,Qingdao 266071,Shandong,China)
關鍵詞:
慢性乙型肝炎聚乙二醇干擾素富馬酸替諾福韋
Keywords:
Chronic hepatitis BPegylated interferonTenofovir fumarate
分類號:
R512.62
DOI:
10.3969/j.issn.1006-1959.2020.04.046
文獻標志碼:
A
摘要:
目的 探討聚乙二醇干擾素α-2b(Peg-INF α-2b)聯合富馬酸替諾福韋治療慢性乙型肝炎早期的臨床療效。方法 選擇2018年6月~2019年6月我院就診的慢性乙型肝炎患者62例,隨機分為對照組(35例)和觀察組(27例),對照組給予聚乙二醇干擾素治療,觀察組在此基礎上聯合替諾福韋治療。比較兩組治療24周HBsAg定量、HBeAg定量、HBV-DNA 定量、ALT、AST、白細胞、中性粒細胞、血小板變化情況。結果 治療24周兩組均未出現HBsAg轉陰,且兩組HBsAg下降幅度比較,差異無統計學意義(P>0.05);實驗組HBeAg下降幅度大于對照組,差異有統計學意義(P<0.05);但兩組HBeAg轉陰率比較,差異無統計學意義(P>0.05)。治療24周,對照組HBV-DNA轉陰率低于觀察組,差異有統計學意義(P<0.05)。兩組ALT、AST下降幅度,白細胞、中性粒細胞及血小板水平,流感樣癥狀、骨髓抑制及脫發發生率比較,差異均無統計學意義(P>0.05)。結論 聚乙二醇干擾素聯合富馬酸替諾福韋治療慢性乙型肝炎24周HBV-DNA轉陰率高,HBeAg下降幅度大,HBsAg、HBeAg轉陰率及患者肝功能改善效果尚不明顯,同時兩藥聯用不增加不良反應。
Abstract:
Objective To investigate the early clinical efficacy of pegylated interferon α-2b (Peg-INF α-2b) combined with tenofovir fumarate in the treatment of chronic hepatitis B.Methods 62 patients with chronic hepatitis B who were treated in our hospital from June 2018 to June 2019 were randomly divided into a control group (35 cases) and an observation group (27 cases). The control group was treated with pegylated interferon The observation group was combined with tenofovir treatment on this basis. Changes in HBsAg quantification, HBeAg quantification, HBV-DNA quantification, ALT, AST, white blood cells, neutrophils, and platelets were compared between the two groups after 24 weeks of treatment.Results There was no HBsAg to negative in the two groups after 24 weeks of treatment, and there was no significant difference in the decrease in HBsAg between the two groups(P>0.05). The decrease in HBeAg was greater in the experimental group than in the control group,the difference was statistically significant(P<0.05).However, there was no significant difference in the HBeAg to negative rate between the two groups(P>0.05).After 24 weeks of treatment, the HBV-DNA negative rate in the control group was lower than that in the observation group,the difference was statistically significant(P<0.05).There was no significant difference in the decrease in ALT, AST, leukocyte, neutrophil, and platelet levels, the incidence of influenza-like symptoms, bone marrow suppression, and hair loss between the two groups(P>0.05).Conclusion Pegylated interferon combined with tenofovir fumarate in the treatment of chronic hepatitis B has a high HBV-DNA negative rate for 24 weeks, a large decrease in HBeAg, and no significant improvement in HBsAg, HBeAg negative rate and liver function. At the same time, the combination of two drugs did not increase adverse reactions.

參考文獻/References:

[1]王貴強,王福生,成軍,等.慢性乙型肝炎防治指南(2015年版)[J].中華實驗和臨床感染病雜志(電子版),2015,9(5):6-25. [2]李濤.ADAR1和ADAR2通過對MAVS基因的3’UTR進行RNA編輯影響HBV表達機制的研究[D].北京協和醫學院,2017. [3]陳炎,陳亞蓓,陶榮芳.2018年美國《慢性乙型肝炎指導意見》介紹:慢性乙型肝炎特殊人群管理及治療推薦更新[J].中國實用內科雜志,2018,38(S1):35-38. [4]Cooksley WG,Piratvisuth T,Lee SD,et al.Peginterferon alpha-2a(40 kDa):an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B[J].Journal of Viral Hepatitis,2003,10(4):298-305. [5]林志鵬,蘇密龍,蘇智軍,等.替諾福韋聯合聚乙二醇干擾素α2a注射液治療耐藥慢性乙型病毒性肝炎患者的臨床研究[J].中國臨床藥理學雜志,2018(2):108-110. [6]婁鑫,郜玉峰,葉珺,等.聚乙二醇干擾素α-2a初治HBeAg陽性慢性乙型肝炎患者的效果及預測因素分析[J].臨床肝膽病雜志,2018,34(05):995-1000. [7]Ferrari C.HBV and the immune response[J].Liver International,2015,35(Suppl1):121-128. [8]劉偉,楊智,仝巧云.乙型肝炎病毒e抗原抑制Fas介導的肝細胞凋亡[J].華中科技大學學報(醫學版),2019,48(2):21-26. [9]梁冰,殷海燕.聚乙二醇干擾素聯合恩替卡韋治療慢性乙肝的臨床分析[J].中國繼續醫學教育,2018,10(29):135-137.

相似文獻/References:

[1]林曉嵐,鄭麗花,陳苑莉,等.微信隨訪對慢性乙型肝炎患者抗病毒治療效果和 生活質量的影響研究[J].醫學信息,2018,(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
 LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,(04):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林曉嵐,陳苑莉.慢性乙型肝炎患者治療依從性及其對生活質量的影響[J].醫學信息,2018,(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
 LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,(04):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]吳 剛,吳錦瑜.HBeAg陰性慢性乙型肝炎患者血清25-羥基維生素D3的檢測及臨床意義[J].醫學信息,2018,(19):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
 WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,(04):96.[doi:10.3969/j.issn.1006-1959.2018.19.028]
[4]葉向榮.恩替卡韋治療慢性乙型肝炎病毒感染的臨床價值評價[J].醫學信息,2018,(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
 YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,(04):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[5]汪曉鳳,邵和軍.慢性乙型肝炎抗病毒治療進展[J].醫學信息,2019,(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
 WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[6]傅 蕊,李士欣,周國強,等.床旁超聲預測慢性乙型肝炎患者胃鏡檢查圍麻醉期誤吸風險的臨床價值[J].醫學信息,2019,(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
 FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Medical Information,2019,(04):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[7]張媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的臨床特點[J].醫學信息,2019,(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
 ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Medical Information,2019,(04):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[8]羅 丹,梁惠卿,吳耀南.吳耀南教授基于“伏邪”理論治療慢性乙肝的驗案舉隅[J].醫學信息,2019,(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[9]周騰騰,鄭 瑩,梁恵卿,等.蛋白質組學在慢性乙型肝炎常見中醫證型中的研究[J].醫學信息,2019,(20):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
 ZHOU Teng-teng,ZHENG Ying,LIANG Hui-qing,et al.Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B[J].Medical Information,2019,(04):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
[10]陳 歡,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].醫學信息,2019,(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
 CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,(04):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]

更新日期/Last Update: 2020-02-15
中国足彩网竞彩 快乐赛车是国家福利彩票 云南快乐10分规律 12036期博彩老头 广东11选五前一稳赚技巧 陕西高频十一选五推荐号 恒瑞财富网 贵州快3一定牛软件 新疆11选5杀号技巧 安徽快三遗漏走势图 在线论坛好棒杨方配资